drugset
Drugs / SB-751689
last change Jun 2011 re-read 9 days ago

SB-751689

targets CASR via inhibition

Developed for
osteoporosis
Investigated by
GlaxoSmithKline

Trials 8

today NCT00548496 · Ph 2 NCT00532077 · Ph 1 NCT00508534 · Ph 1 NCT00468689 · Ph 1 NCT00499928 · Ph 1 NCT00540878 · Ph 1 NCT00554255 · Ph 1 NCT00388596 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT00532077 Aug 2007 → Jan 2008 osteoporosis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00508534 Jul → Aug 2007 osteoporosis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00468689 Apr → Aug 2007 osteoporosis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00499928 Apr → Jul 2007 osteoporosis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00540878 Apr 2007 → ? osteoporosis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00554255 Oct → Dec 2006 osteoporosis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00388596 Oct 2006 → ? osteoporosis GlaxoSmithKline Completed No outcome recorded
Phase 21 trial · 1 missed
Phase 2 NCT00548496 Sep 2007 → Nov 2008 — GlaxoSmithKline Terminated Missed primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as SB-751689 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00540878 ↗
7

NCT00508534 ↗

NCT00554255 ↗

NCT00468689 ↗

NCT00532077 ↗

NCT00548496 ↗

NCT00388596 ↗

NCT00499928 ↗
Action Inhibit “[14C]-SB-751689 (a Calcium-Sensing Receptor Antagonist)” NCT00499928 ↗
Route Oral “SB-751689 oral tablets (100 and 400 ng)” NCT00468689 ↗
Target CASR “ronacaleret, a novel calcium-sensing receptor antagonist” PMID 21742071 ↗ Jun 2011